ObjectiveTo explore the clinical efficacy of ulinastatin combined with octreotide in the treatment of patients with severe acute pancreatitis. MethodsA total of 96 patients with severe acute pancreatitis admitted to our hospital from April 2018 to June 2020 were selected as the research objects, and they were divided into two groups by the random number method, with 48 cases in each group. The patients in the control group were treated with octreotide, whereas the patients in the observation group were treated with ulinastatin combined with octreotide, for 7 days of the treatment course. The total effective rate of treatment was compared between the two groups. The symptom disappearance time, gastrointestinal function recovery time, physical sign disappearance time, blood amylase and urine amylase recovery time, and hospital stays were compared between the two groups. ResultsThe total effective rate of treatment in the observation group (91.7%) was significantly higher than that in the control group (75.0%), and the difference was statistically significant (P＜0.05). The symptom disappearance time, gastrointestinal function recovery time, physical sign disappearance time, blood amylase and urine amylase recovery time, and hospital stays in the observation group were significantly shorter than those in the control group, with statistically significant differences (P＜0.05). ConclusionUlinastatin combined with octreotide has a definite clinical efficacy in the treatment of patients with severe acute pancreatitis, which can effectively alleviate the clinical symptoms of the patients, significantly decrease the blood and urine amylase levels, significantly shorten hospital stays, and promote recovery in patients.

无